Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 3
1959 1
1965 2
1966 1
1973 1
2012 1
2016 1
2018 2
2019 1
2020 1
2022 5
2023 2
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand E, et al. Among authors: delev n. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369798 Free PMC article. Clinical Trial.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N. Merrill JT, et al. Among authors: delev n. N Engl J Med. 2022 Mar 17;386(11):1034-1045. doi: 10.1056/NEJMoa2106535. N Engl J Med. 2022. PMID: 35294813 Clinical Trial.
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.
Connelly K, Eades LE, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, Gregory K, Brunner H, Burke L, Arnaud L, Askanase A, Aranow C, Vital E, Pons-Estel G, Dantata K, Andersen J, Cornet A, Buie J, Sun Y, Tanaka Y, Simon L, Lahoud Y, Friedman A, Kalunian K, Zuraw Q, Werth V, Garces S, Morand EF; TRM-SLE Consortium. Connelly K, et al. Nat Rev Rheumatol. 2023 Sep;19(9):592-602. doi: 10.1038/s41584-023-00993-7. Epub 2023 Jul 11. Nat Rev Rheumatol. 2023. PMID: 37433880 Review.
Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study.
Connelly K, Koelmeyer R, Ayton D, May J, Gregory K, Eades LE, Barallon R, Kandane-Rathnayake R, Golder V, Anzum A, Mydin M, Akther M, Friedman A, Askanase AD, Aranow C, Vital E, Pons-Estel G, Brunner H, Kalunian K, Dantata K, Arnaud L, Burke L, Simon LS, Zuraw Q, Garces S, Werth VP, Sun YB, Tanaka Y, Lahoud Y, Cornet A, Sorrentino A, Rahman A, Stevens A, Barbey C, Dey ID, Karis E, Bonfá E, Noss E, Smith EMD, Stojan G, Andersen J, Merola JF, Ross Terres JA, Buie J, Maller J, Mosca M, Hojnik M, Dall'Era M, Furie RA, van Vollenhoven RF, Banerjee S, Morand E; TRM-SLE Taskforce Members; Delphi Participants. Connelly K, et al. Lupus Sci Med. 2025 May 6;12(1):e001484. doi: 10.1136/lupus-2024-001484. Lupus Sci Med. 2025. PMID: 40328675 Free PMC article.
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Morand EF, Pike M, Merrill J, F van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand EF, et al. Among authors: delev n. Expert Opin Investig Drugs. 2024 May;33(5):431-440. doi: 10.1080/13543784.2024.2337736. Epub 2024 May 29. Expert Opin Investig Drugs. 2024. PMID: 38807572 Free article.
Ileo-urethroplastica perinealis.
DELEV N. DELEV N. Br J Urol. 1959 Sep;31:327-31. doi: 10.1111/j.1464-410x.1959.tb09426.x. Br J Urol. 1959. PMID: 13815626 No abstract available.
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
Lipsky PE, Vollenhoven RV, Dörner T, Werth VP, Merrill JT, Furie R, Petronijevic M, Velasco Zamora B, Majdan M, Irazoque-Palazuelos F, Terbrueggen R, Delev N, Weiswasser M, Korish S, Stern M, Hersey S, Ye Y, Gaudy A, Liu Z, Gagnon R, Tang S, Schafer PH. Lipsky PE, et al. Among authors: delev n. Ann Rheum Dis. 2022 Jul 12;81(8):1136-1142. doi: 10.1136/annrheumdis-2022-222212. Ann Rheum Dis. 2022. PMID: 35477518 Free PMC article.
23 results